[滤泡性淋巴瘤]

[Follicular lymphoma].

作者信息

Tomita Naoto

出版信息

Nihon Rinsho. 2014 Mar;72(3):488-92.

Abstract

Follicular lymphoma (FL) is the most popular indolent lymphoma. In discussing the appropriate first-line therapy, FL patients are divided into 3 clinical categories: 1) localized-stage FL in which local irradiation is recommended and 30-50% of patients experience long progression-free survival, 2) low-tumor burden advanced-stage FL in which watchful waiting strategy is generally recommended, 3) high-tumor burden advanced-stage FL in which CHOP plus rituximab(R) is recommended and bendamustine plus R is a potent therapeutic option. In relapsed/refractory FL, re-biopsy is needed to evaluate the possible histological transformation to diffuse large B-cell lymphoma. Relapsed/refractory FL patients should be registered in clinical study because the optimal treatment in such patients is unconfirmed.

摘要

滤泡性淋巴瘤（FL）是最常见的惰性淋巴瘤。在讨论合适的一线治疗方案时，FL患者被分为3种临床类型：1）局限性FL，推荐局部放疗，30%-50%的患者可获得较长的无进展生存期；2）低肿瘤负荷晚期FL，通常推荐观察等待策略；3）高肿瘤负荷晚期FL，推荐CHOP方案加利妥昔单抗（R），苯达莫司汀加利妥昔单抗也是一种有效的治疗选择。对于复发/难治性FL，需要再次活检以评估是否可能发生组织学转化为弥漫性大B细胞淋巴瘤。复发/难治性FL患者应登记参加临床研究，因为此类患者的最佳治疗方案尚未确定。